Beta and alpha-2 adrenergic receptors appeared to be positively and negatively coupled to adenylate cyclase, respectively. Cells or cell membranes were incubated with epinephrine (10 ,M) alone and in combination with the antagonists yohimbine (alpha-2) and prazosin (alpha-i). Epinephrine alone prompted a modest increase in adenylate cyclase activity, cyclic AMP, and glycerol release, an index of lipolysis. Yohimbine (0.1 ,tM) greatly enhanced these actions whereas prazosin was without effect. The beta agonist, isoproterenol, stimulated glycerol release, whereas the alpha-2 agonist, clonidine, inhibited lipolysis and cyclic AMP accumulation.
INTRODUCTION
Over 30 yr ago, Ahlquist (1) proposed that the cellular responses to epinephrine, norepinephrine, and the synthetic catecholamine, isoproterenol, could be divided into two groups, which he designated alpha and beta, according to their potencies in interacting with the proposed receptors. With alpha-mediated responses, epinephrine was most potent and isoproterenol least potent; with beta-mediated responses, isoproterenol was most active and norepinephrine least so. Subsequently, Lands et al. (2) suggested that beta receptors could be further divided into two groups, beta-i and beta-2. Both beta-i and beta-2 receptors appear to stimulate adenylate cyclase leading to an increase in cyclic AMP and to an expression of the tissue-specific function. More recently, alpha receptors have been divided into alpha-i and alpha-2 subtypes (3) (4) (5) . Although the initial classification was based on anatomic localization, it appears that a classification related to function is more reasonable (3, 4) . The means by which alpha adrenergic stimulation affects cellular function is not completely understood. In sites decreases cyclic AMP through adenylate cyclase inhibition (4, 5) .
The human adipocyte is of interest because it is a single cell type that has both alpha and beta receptors. Catecholamines seeril to be physiologically important mediators for lipid 'mijbilization in these cells (6) (7) (8) (9) (10) (11) (12) (13) . Beta adrenergic stimulation increases adenylate cyclase activity, raises cyclic AMP, and enhances the cyclic AMP-dependent processes such as lipolysis, whereas alpha adrenergic activation, in general, has opposite effects (6) (7) (8) (9) (10) (11) (12) (13) . These observations support the hypothesis put forward by Robison et al. (14) that some cell types have both alpha and beta adrenoceptors that mediate opposite effects on cyclic AMP and cell function. The studies reported here were carried out to characterize further the adrenergic receptors of human adipocytes and the metabolic functions they subserve by using selective agonists and antagonists.
METHODS
Cell preparation. Abdominal adipose tissue samples were obtained from subjects undergoing elective abdominal surgery. Informed consent, approved by the institution's Human Experimentation Committee, was obtained from each subject. Because all subjects were infused with 5% dextrose during surgery, they were considered to be in the fed state. Fat cells were obtained by collagenase digestion of adipose tissue (15) . For experiments involving measurement of cyclic AMP and glycerol release, cells were isolated and then suspended in Krebs bicarbonate buffer containing 4% bovine serum albumin and 2.5 mM glucose. Flasks containing portions of cell suspensions were incubated with gentle shaking in an atmosphere of 95% 02 and 5% CO2. Fat cell ghosts were prepared by hypotonic lysis at 10°C with 5 mM Tris HCI buffer (pH 7.5, 25°C) containing 2.5 mM MgCl2 and 1 mM EDTA as described by Bimbaumer et al. (16) .
Radioligand binding assays. Binding studies with dihydroalprenolol, p-aminoclonidine, and WB4101 were performed using membranes prepared from adipocyte ghosts stored at -20°C for [1] [2] [3] [4] Beta adrenergic receptors were assayed as described previously (17 NH40H (130:70:5:5) . This procedure was suitable for the separation of phosphatidylcholine, phosphatidylethanolamine, and phosphatidylinositol. Phosphatidic acid was not separated from phosphatidylserine, which migrated only slightly above the origin. Although the amount of phosphatidylserine plus phosphatidic acid may be overestimated by the presence of some contaminants at the origin, nearly all the radioactivity corresponded with phosphatidic acid. The same comment is applicable to phosphatidylinositol caused by incomplete separation from sphingomyelin. The incorporation of label into phosphatidylserine or sphingomyelin is less than 10% of that of phosphatidic acid or phosphatidylinositol in rat adipocytes (23) . There is no effect of catecholamines on the labeling of phosphatidylserine or sphingomyelin in rat adipocytes (23) . Lipids were visualized by iodine vapor staining. The phosphorus content of phospholipids was determined by a micro modification of the procedure of Bartlett (24) Table I ) in which the protein concentration was 0.11 mg/ml.
and alpha-i receptor densities were more variable. The ratio of dihydroalprenolol binding to that of p-aminoclonidine was 1.8+0.4 (mean±+SEM) whereas the ratio of dihydroalprenolol to WB4101 binding was 1.0+0.2. For all three receptors, the KD was relatively constant among the different preparations.
[3H]dihydroergocryptine, an alpha antagonist, labels alpha-i and alpha-2 receptors with equal affinity in a variety of systems (26) . In membranes derived from subcutaneous human adipose tissue, [3H]dihydroergocryptine binding is saturable and of high affinity.
The KD was 1.2 nM, and the Bmax was 120±+18 fmol/mg protein (n = 7). In an effort to determine whph alphaadrenergic receptor subtype(s) were present in these adipocyte membranes, competition curves of [3H]-dihydroergocryptine were performed with several antagonists (26, 27) (Fig. 3) . The alpha-2-selective qptagonist yohimbine was much more potent ( isoproterenol (pure beta), epinephrine (mixed alpha/ beta), methoxamine (alpha-i) or clonidine (partial alpha-2), and glycerol release measured after 4-h incubation (Fig. 4) . Isoproterenol stimulated lipolysis substantially, epinephrine was less potent, methoxamine had little or no effect, and clonidine depressed Bmax (receptor density, femtomoles per milligram protein) and KD (affinity, nanomolar) were determined for each receptor as described in Fig. 1 . Each preparation is from a different patient.
basal glycerol release (Fig. 4) . In other experiments, epinephrine (10 ,uM) was incubated in the presence of increasing concentrations of the antagonist yohimbine (alpha-2), phentolamine (alpha-i and alpha-2), or prazosin (alpha-i). At a concentration of 0.1 ,uM both yohimbine and phentolamine enhanced epinephrine stimulated lipolysis whereas prazosin even at 10 ,uM was without effect (Fig. 5 ). Cells were incubated with clonidine and methoxamine, and, in other experiments, with epinephrine alone and in combination with varying concentrations of the antagonist yohimbine, phentolamine, and prazosin. Cyclic AMP was estimated at the end of a 20-min incubation. Clonidine depressed basal cyclic AMP accumulation whereas methoxamine even at 0.1 mM was without effect (Fig. 6 ). Yohimbine and phentolamine both markedly enhanced epinephrine-stimulated cyclic AMP whereas prazosin was without effect (Fig. 7) . Isoproterenol (10 FLM) elevated cyclic AMP from a basal value of 55 to 9,980 pmol/105 cells (data not shown) whereas epiinephrine 10 nucleotide only to 90 pmol/106 cells. If the failure of epinephrine to elevate cyclic AMP to the same extent as isoproterenol were caused by concurrent stimulation of alpha-2 receptors, one would expect yohimbine and phentolamine to enhance the epinephrine stimulation and prazosin to have no effect. The results were as predicted and indicate the presence of alpha-2 catecholamine receptors, which inhibit both lipolysis and cyclic AMP accumulation (Figs. 5 and 6 ). Fat cell ghosts were incubated for 15 min with epinephrine 10 ,uM alone and with increasing concentrations of yohimbine, phentolamine, and prazosin. None of the antagonists affected basal adenylate cyclase activity (data not shown). Both yohimbine and phentolamine enhanced the stimulating action of epinephrine on enzyme activity whereas prazosin was withouit effect (Fig. 8) . Alpha-i adrenergic response: stimulation of phospholipid turnover. The phospholipid composition and the incorporation of radioactive phosphate into major phospholipids in human fat cells were similar to those observed in rat and hamster adipocytes (5, 23) . Under basal conditions, phosphatidic acid and phosphatidylserine contained 20±t2% (mean and SEM of four experiments) of the total phosphate, phosphatidylinositol, and sphingomyelin, 15+1%, phosphatidylcholine, 28±1%, phosphatidylethanolamine 30±2%, and cardiolipin 7±1%. The incorporation of radioactive phosphate was mainly into phosphatidylcholine (67±11% of the total incorporation into phospholipids), phosphatidic acid plus phosphatidylserine (24±10%), and phosphatidylinositol (6±1%). Less incorporation was observed into phosphatidylethanolamine (3±1%) and cardiolipin (<1%). The values are the means±SEM of four experiments.
Epinephrine produced a dose-dependent increase in the incorporation of radioactive phosphate into phosphatidylinositol and phosphatidic acid (Fig. 9) . A small decrease in the labeling of phosphatidylethanolamine and phosphatidylcholine was observed at concentrations of epinephrine above 10 ,uM (Fig. 9) , whereas the labeling of cardiolipin was not affected by 10 ,M epinephrine (Table II) . The decrease in the labeling of phospholipids at high concentrations of epinephrine was previously observed in rat adipocytes and attributed to intracellular accumulation of free fatty acids (23) . The pure beta adrenergic agent, isoproterenol, did not mimic the effect of epinephrine on the labeling of phosphatidylinositol and phosphatidic 0.1 pM 1jM 10plM EPINEPHRINE 0.1 mM FIGURE 9 Stimulation of 32P uptake into phosphatidic acid (PA) and phosphatidylinositol (PI) by epinephrine. Adipocytes were incubated with increasing concentrations of epinephrine. Basal values are given in Table II . The values given are the means + SE M of four paired experiments. There was little or no effect of epinephrine on phosphatidylcholine (PC) or phosphatidylethanolamine (PE) turnover.
acid indicating that this effect of epinephrine is mediated through the stimulation of alpha receptors (Table  II) . Furthermore, the action of epinephrine on phosphatidylinositol labeling was actually greater in the presence of the beta adrenergic blocking agent, propranolol (Table II) . Propranolol itself produced a small increase in labeling of phosphatidylinositol and phosphatidic acid (Table II) . This effect of propranolol has been observed in the rat adipocyte (23) , and in other tissues (28, 29) but seems to be caused by its local anesthetic properties rather than by its action as a beta' blocker.
The stimulation by epinephrine of 32P incorporation into phosphatidylinositol and phosphatidic acid was blocked by selective alpha adrenergic antagonists (Fig. 10) . The potency order was prazosin > phentolamine > yohimbine, indicating that this action of epinephrine is mediated by the activation of alpha-I adrenoceptors. Prazosin (1 ,uM), phentolamine (10 ,uM), and yohimbine (0.1 mM) each alone did not modify the labeling of phospholipids (Table II) .
DISCUSSION
The principal finding of these studies is that a single type of cell, the human adipocyte, appears to have three different types of adrenergic receptors, each coupled to a distinct biochemical response: beta, activation of adenylate cyclase; alpha-2, inhibition of adenylate cyclase; and alpha-i, stimulation of phosphatidylinositol turnover. The data supporting this conclusion derive from two different types of experiments: (a) the binding of specific radioligands, and (b) the effects of pharmacological agents on receptor-specific biochemical responses. 472 Burns et al. alpha receptor has been controversial. We (6) andl others (13) have obtained various evidence suggesting that the decrease in lipolysis and in cyclic AMP conicentration resulting from alpha stimulation of the human adipocyte is mediated by the inhibition of adenylate cyclase. The present studies confirm these results and, in addition, define this alpha responise as being of the alpha-2 subtype. A similar conclusioni was also reached by Lafontan and Berlan (30) based on agonist inhibition of theophylline-inducedl lipolysis in human adipocytes and antagonism of clonidinie action. It appears that the alpha-2 receptor in a numlliber of other tissues and species may also be negatively coupled to adenylate cyclase (4, 5) . Alpha-i stimulation in the human adipocyte results in the increased turnover of phosphatidylinositol and phosphatidic acid. It is thought that the increased turnover of these phospholipids in many tisstues results in an increase in the cytoplasmic calcium ion concentration (4, 31, 32). For example, in the rat adipocyte alpha-i adrenergic stimulation results both in an increase in phosphatidylinositol turnover and the inactivation of glycogen synthase (33) . This inactivation can be mimicked by the divalent cation ionophore A23187 (34, 35) . There is little effect of either alpha-I adrenergic activation or the divalent cation ionophore A23187 on cyclic AMP accumulation and lipolysis in hamster or rat adipocytes (5, 36, 37) . Michell and his associate (31, 32) have pointed out the remarkable correlation between these two processes and suggested that turnover of phosphatidylinositol is involved in some fashion in the gating or mobilization of calcium. However, the link between the ability of alpha-I catecholamines to elevate cytosolic calcium in many Characterization of Adrenergic Receptors in Human Adipocytes cells and increased turnover of phosphatidylinositol is not yet proven (31, 32) .
Each of the radioligands used in the binding studies exhibited high affinity and saturable binding to a single class of binding sites. The affinity of each radioligand at its receptor binding site and the density of receptor binding sites found in the human adipocyte are similar to those in other adipocytes (5, 38) . Preliminary results of studies in progress using unlabeled adrenergic agents are consistent with the conclusion that the radioligands are specifically labeling the appropriate receptors (Bylund, D. B. Unpublished data). For example, isoproterenol is more potent in inhibiting [3H]-dihydroalprenolol binding than is either epinephrine or norepinephrine. Furthermore, prazosin, an alpha-i antagonist, was considerably more potent in inhibiting [3H]WB4101 binding than [3H]para-aminoclonidine, whereas yohimbine, an alpha-2 antagonist, was more potent on [3H]para-aminoclonidine binding. It is particularly noteworthy that whereas properitoneal and subcutaneous adipose tissue appear to have similar levels of alpha-2 receptors, the former has O-50% more alpha-i than alpha-2, while alpha-i receptors were not detected in the latter.
The ability to study the three adrenergic receptors of the human adipocyte on the basis of both binding and biochemical response should provide an excellent model system for the study of the regulation, function, and interrelationships of the various adrenergic receptors. Circumstances that may modify the balance between alpha-2 and beta receptors, e.g., fasting (39) and hypothyroidism (12, 40) should be especially interesting experimental paradigms.
